Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
Mulu Z. Tesfay, Aleksandra Cios, Zetao Cheng, Khandoker Usran Ferdous, Randal S. Shelton, Bahaa Mustafa, Natalie M. Elliott, Elizabeth A. Raupach, Camila Simões, Isabelle Racine Miousse, Alicja Joanna Urbaniak, Michael Bauer, Eric R. Siegel, Steven R. Post, Jean Christopher Chamcheu, , Bolni Marius Nagalo
Oncolytic virus-based delivery of an alloantigen improves antitumor immunity and synergizes with immune checkpoint inhibitors in pancreatic cancer.
Journal for ImmunoTherapy of Cancer · May 1, 2026Peer-reviewedCancer Biology